Hodgkin's Disease: Basing Treatment Decisions on Prognostic Factors

References

• Urba W. J., Longo D. L. Hodgkin's disease. N. Engl. J. Med. 1992; 326: 678
   PubMed Web of Science ®Google Scholar
• Faguet G. B., Davis H. C. Survival in Hodgkin's disease: the role of immunocompetence and other risk factors. Blood 1982; 59: 938
   PubMed Web of Science ®Google Scholar
• Lister T. A., Crowther D., Sutcliffe S. B., et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J. Clin. Oncol. 1990; 8: 1602
   Google Scholar
• Tirelli U., Errante D., Vaccher E., et al. Hodgkin's disease in 92 patients with HIV infection: The Italian experience. Ann. Oncol. 1992; 3(suppl 4)S69
   PubMedGoogle Scholar
• Hopper K. D., Diehl L. F., Lesar M., et al. Hodgkin's disease: clinical utility of CT in initial staging and treatment. Radiology 1988; 169: 17
   PubMed Web of Science ®Google Scholar
• Mansfield C. M., Fabian C., Jones S., et al. Comparison of lymphangiography and computed tomography scanning in evaluating abdominal disease in stages III and IV Hodgkin's disease. Cancer 1990; 66: 2295
   PubMed Web of Science ®Google Scholar
• Hagemeister F. B., Fesus S. M., Lamki L. M., et al. The role of the gallium scan in Hodgkin's disease. Cancer 1990; 65: 1090
   PubMed Web of Science ®Google Scholar
• Bergsagel D. E., Alison R. E., Bean H. A., et al. Results of treating Hodgkin's disease without a policy of laparotomy staging. Cancer Treat Rep. 1982; 61: 717
   Google Scholar
• Ambrosetti A., Nadali G., Vinante F., et al. Serum levels of soluble interleukin-2 receptor in Hodgkin's disease. Relationship with clinical stage, tumor burden and treatment outcome. Cancer 1993; 72: 201
   PubMed Web of Science ®Google Scholar
• Kurzrock R., Redman J., Cabanillas F., et al. Serum inter-leukin-6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease with B symptoms. Cancer Res. 1993; 53: 2118
   PubMed Web of Science ®Google Scholar
• Travis L. B., Curtis R. E., Wankey B. F., et al. Second cancers in patients with chronic lymphocytic leukemia. J. Natl. Cancer Inst. 1992; 16: 1422
   Web of Science ®Google Scholar
• Longo D. L., Russo A., Duffey P. L., et al. Treatment of advanced stage massive mediastinal Hodgkin's disease: the case for combined modality treatment. J. Clin. Oncol. 1991; 9: 227
   PubMed Web of Science ®Google Scholar
• Pronitz L. R., Farber L. R., Kapp D. S., et al. Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data. J. Clin. Oncol. 1988; 6: 603
   PubMed Web of Science ®Google Scholar
• Longo D. L., Youg R. C., Wesley M., et al. Twenty years of MOPP therapy for Hodgkin's disease. J. Clin. Oncol. 1986; 4: 1295
   PubMed Web of Science ®Google Scholar
• Straus D. J., Gaynor J. J., Myers J., et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating, potentially non-cross-resistant chemotherapy and intermediate-dose radiation therapy. J. Clin. Oncol. 1990; 8: 1173
   PubMed Web of Science ®Google Scholar
• Ekert H., Waters K. D., Smith P. J., Toogood I., Mauger D. Treatment with MOPP or ChlVPP chemotherapy only for all stages of Hodgkin's disease. J. Clin. Oncol. 1986; 6: 1845
   Web of Science ®Google Scholar
• van Rijswijk R. E. N., Haanen C., Dekker A. W., et al. Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. J. Clin. Oncol. 1989; 7: 1776
   PubMed Web of Science ®Google Scholar
• Rubin P., Constine L., Bennett J. M. Hodgkin's disease: IIB or not to be-using irradiation alone or in combination with chemotherapy? That is the question1. J. Clin. Oncol. 1986; 4: 1551
   PubMedGoogle Scholar
• Lister J. A., Dorereen M. S., Faux M., et al. The treatment of stage IIIA Hodgkin's disease. J. Clin. Oncol. 1983; 1: 745
   PubMed Web of Science ®Google Scholar
• Santoro A., Viviani S., Villareal C. J., et al. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP. Cancer Treat Rep. 1986; 79: 343
   Google Scholar
• Viviani S., Santoro A., Negroes E., et al. Hodgkin's disease: results in patients relapsing more than 12 months after first complete remission. Ann. Oncol. 1990; 1: 123
   PubMed Web of Science ®Google Scholar
• Fisher R. I., De Vita V. T., Hubbard S. M., et al. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann. Intern. Med. 1979; 90: 761
   PubMed Web of Science ®Google Scholar
• Gajiewski J. L., Sobocinski K., Bortin M. M., et al. Results of HLA-identical bone marrow transplants for Hodgkin's disease. Blood 1993; 82(suppl 1)147a, (abstract 573)
   Google Scholar
• Ahmed T., Cook P., Beer M., et al. Factors influencing survival in relapsed or refractory Hodgkin's disease treated by high-dose chemotherapy and autologous bone marrow transplant. Blood 1993; 82(suppl 1)147a, (abstract 572)
   Google Scholar
• Seymour L., Dansey R., Bezwoda W. R. High dose etoposide and melphalan with non-cryopreserved marrow rescue in refractory and relapsed Hodgkin' s disease. Blood. 1993; 82(suppl 1)172a, (abstract 672)
   Google Scholar
• Khwaja A., Goldstone A. H., Linch D. C. Patients with delayed neutrophil recovery after autologous bone marrow transplantation (ABMT) for lymphoma not receiving haemopoietic growth factors do not have increased mortality from infection. Blood 1993; 82(suppl 1)424a, (abstract 1680)
   Google Scholar
• Bierman P., Vose J., Anderson J., et al. Comparison of autologous bone marrow transplantation (ABMT) with peripheral stem cell transplantation (PSCT) for patients with Hodgkin's disease. Blood 1993; 82(suppl 1)445a, (abstract 1765)
   PubMedGoogle Scholar
• Horning S. J., Negrin R. S., Chao N. J., et al. Autologous stem cell transplantation for recurrent of refractory Hodgkin's disease: Comparative results of total body irradiation and chemotherapy-only high dose regimens. Blood 1993; 82(suppl 1)445a, (abstract 1766)
   PubMedGoogle Scholar
• Schmitz N., Dreger P., Zander A., et al. A randomized, controlled, multicenter study of granulocyte colony stimulating factor (Filgrastin) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Blood 1993; 82(suppl 1)146a, (abstract 568)
   Google Scholar
• Carella A. M., Congiu A. M., Gaozza E., et al. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report. J. Clin. Oncol. 1988; 6: 1411
   PubMed Web of Science ®Google Scholar
• Surbone A., Armitage J. O., Gale P. P. Auto-transplantation in lymphoma: better therapy or healthier patients?. Ann Intern. Med. 1991; 114: 1059
   PubMed Web of Science ®Google Scholar
• Nissen N. I., Hovgaard D. Controversies in the management of Hodgkin's disease. Eur. J. Cancer 1991; 27: 306
   PubMed Web of Science ®Google Scholar
• Gullati S. C., Bennett L. C. Granulocyte-macrophage colony stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin's disease. Ann. Intern. Med. 1992; 116: 177
   PubMed Web of Science ®Google Scholar
• Schwartz G., Tepler L., Charette J., et al. Complete response of a Hodgkin's lymphoma in a phase I trial of DAB468IL-2, an IL-2-Diphteria fusion toxin. Blood 1991; 78(1)175A
   PubMedGoogle Scholar